Atrogi announces first subjects dosed in human trial for lead candidate ATR-258
- First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight loss
- Study led by Associate Professor Morten Hostrup, a leading authority on β2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle physiological aspects of ATR-258’s highly selective β2-adrenergic signaling
- Atrogi’s breakthrough technology, validated by publication of landmark research in Cell in June 2025, enables, for the first time, development of next-generation, highly selective β2-agonists for chronic use
Stockholm, Sweden, March 18, 2026 – Atrogi AB, a clinical stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces that the first subjects have been dosed in a human trial for its lead candidate, ATR-258, evaluating the muscle physiological effects of its highly selective GRK-targeted β2-adrenergic signaling pathway.
